Dec 22 2025 12:00 AM EST
Amicus Therapeutics: Rare Disease Royalty Gets a $4.8 Billion Coronation
Amicus Therapeutics (NASDAQ: FOLD) didn’t just catch the market’s eye—it drew a royal decree. Over the past five days, shares have rocketed 30.3%, crowning a year-to-date climb of 44.7%. The spark? A $4.8 billion all-cash acquisition by BioMarin Pharmaceutical, instantly transforming Amicus from rare disease contender to biotech royalty.
The Art of the Premium: When M&A Becomes an Event
Most acquisitions in biotech land with a thud—this one thundered. BioMarin’s $14.50 per share offer delivered a 33% premium over the last close, instantly re-rating Amicus stock and igniting a rally that outpaced sector averages. The deal, unanimously blessed by both boards, is expected to close in Q2 2026, pending regulatory nods and shareholder approval. But why did Wall Street cheer so loudly?
Galafold and Pombiliti: Blockbusters in the Shadows
It’s rare disease drugs that attract kingmakers. Amicus owns Galafold (Fabry disease) and Pombiliti + Opfolda (Pompe disease), both showing relentless growth. In Q3 2025, Galafold sales hit $138.3 million (up 15% YoY), while Pombiliti + Opfolda soared to $30.7 million (up 45% YoY). Combined, Amicus revenue reached $169.1 million for the quarter, with a gross margin of 89.5%—the kind of efficiency that turns heads from Boston to Basel.
Cash, Leverage, and the New Biotech Math
The financials tell a rare story: Amicus swung to a GAAP net income of $17.3 million in Q3 2025, reversing last year’s $(6.7) million loss. The company’s cash and equivalents stood at $263.8 million, with total assets growing to $868.8 million. Operating margins have swung positive at 5.5%, while net income margin narrowed to -2.3%—a dramatic improvement over -21.2% the prior year. For BioMarin, the acquisition is accretive to Non-GAAP Diluted EPS within 12 months, with substantial upside beginning 2027.
Sectoral Chess: Why Rare Disease Is the Prize
This isn’t just a company story—it’s a sectoral gambit. Rare disease drugs command premium pricing, minimal competition, and extended patent protection. Amicus resolved Galafold’s patent dispute, securing U.S. exclusivity until 2037. With biotech M&A heating up and the global market for rare disease treatments projected to grow at double digits, Amicus became the trophy every player wanted.
A Rally Written in Numbers
In the last three months, Amicus shares have soared 65.5%, and over six months, a jaw-dropping 151.4%. Wall Street loves growth, but it worships certainty—especially when an all-cash buyout removes the usual biotech risk. Institutional investors have piled in, and analyst targets (average: $15.20) now look conservative.
Not Just a Victory—A New Playbook
Amicus Therapeutics didn’t just get acquired—it redefined the M&A playbook for biotech. Blockbuster rare disease assets, stellar revenue growth, and operational discipline converged to create a five-day rally that reverberates across the sector. For investors, it’s a reminder: in biotech, the right molecule—and the right suitor—can still trigger a coronation.